Flash FinanceUS
Market closed · weekend S&P 5007,376.86+0.31% Nasdaq24,579.42+1.09% Dow 3051,285.73-0.46% Russell 20002,754.11+0.89% Nasdaq-10026,989.99+1.35% MidCap 4003,602.50+0.56% SmallCap 6001,673.98+0.05% VIX25.64-9.01% 10Y Yield4.86+0.45% Close of Nov 06, 2026

NeoGenomics Laboratories, Inc. (NEO)

Nasdaq Health Care Health Care Services S&P SmallCap 600
$16.84
+0.35 (+2.12%)
Close of Nov 06, 2026 · end-of-day data
Source: NeoGenomics Laboratories, Inc.'s 10-K / 10-Q XBRL data on SEC EDGAR · fetched Nov 05, 2026

Revenue, net income & free cash flow

Income statement

fiscal years · USD
Fiscal yearFY2016FY2017FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025
Revenue$231.81M$240.25M$276.74M$408.83M$444.45M$484.33M$509.73M$591.64M$660.57M$727.33M
Cost of revenue$133.70M$138.29M$149.48M$211.99M$258.56M$297.27M$321.83M$347.04M$370.47M$413.04M
Gross profit$98.10M$101.96M$127.27M$196.84M$185.89M$187.06M$187.90M$244.60M$290.10M$314.29M
Research & development$4.65M$3.64M$3.00M$8.49M$8.23M$21.87M$30.33M$27.31M$31.16M$37.08M
Operating income$2.15M$2.90M$10.04M$13.01M-$13.99M-$118.75M-$157.62M-$107.74M-$92.11M-$115.88M
Interest expense—$5.54M$6.23M$3.71M$7.02M$8.22M$7.58M$6.91M$6.62M$3.75M
Pre-tax income-$7.84M-$2.65M$3.82M$3.65M-$14.06M-$15.07M-$159.34M-$97.10M-$80.67M-$110.27M
Income tax-$1.70M-$2.25M$1.18M-$4.36M-$18.23M-$6.73M-$15.09M-$9.13M-$1.95M-$2.24M
Net income-$6.14M-$396.00K$2.64M$8.01M$4.17M-$8.35M-$144.25M-$87.97M-$78.73M-$108.03M
EBITDA$18.09M$18.50M$25.84M$33.35M$11.91M-$88.56M-$122.25M-$70.29M-$53.01M-$79.81M
Diluted shares77.54M79.43M91.57M103.61M111.79M119.96M124.22M125.50M126.66M128.10M
Gross margin42.3%42.4%46.0%48.1%41.8%38.6%36.9%41.3%43.9%43.2%
Operating margin0.9%1.2%3.6%3.2%-3.1%-24.5%-30.9%-18.2%-13.9%-15.9%
Net margin-2.6%-0.2%1.0%2.0%0.9%-1.7%-28.3%-14.9%-11.9%-14.9%

Balance sheet

fiscal years · USD
Fiscal yearFY2016FY2017FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025
Cash & equivalents$12.53M$12.82M$9.81M$173.02M$228.71M$316.83M$263.18M$342.49M$367.01M$159.62M
Short-term investments———$0$67.55M$198.56M————
Receivables$55.51M$60.43M$76.92M$94.24M$106.84M$112.13M$119.71M$131.23M$150.54M$159.24M
Inventory$6.25M$7.47M$8.65M$14.40M$29.53M$23.39M$24.28M$24.16M$26.75M$28.57M
Total current assets$78.83M$85.88M$103.67M$290.74M$448.73M$681.51M$605.29M$596.81M$596.02M$376.29M
Goodwill$147.02M$147.02M$197.89M$198.60M$211.08M$527.12M$522.77M$522.77M$522.77M$524.34M
Total assets$337.12M$344.45M$505.01M$709.51M$988.33M$1.87B$1.74B$1.68B$1.64B$1.36B
Total current liabilities$38.11M$36.47M$60.92M$63.90M$73.18M$87.23M$89.93M$96.30M$301.24M$88.30M
Short-term debt$3.75M$3.75M$7.87M$5.00M$0$1.14M$70.00K$0$200.78M$0
Long-term debt$91.95M$91.13M$92.88M$95.03M$169.09M$532.55M$535.32M$538.20M$340.33M$341.86M
Total debt$95.70M$94.88M$100.75M$100.03M$169.09M$533.69M$535.39M$538.20M$541.11M$341.86M
Total liabilities$150.52M$139.88M$184.57M$202.10M$294.04M$761.50M$742.01M$739.69M$735.70M$523.27M
Shareholders' equity$162.32M$171.96M$320.44M$507.41M$694.29M$1.11B$998.02M$941.54M$902.34M$836.56M

Cash flow

fiscal years · USD
Fiscal yearFY2016FY2017FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025
Operating cash flow$21.48M$18.04M$44.79M$23.37M$1.46M-$26.72M-$65.99M-$1.95M$7.02M$5.23M
Capital expenditures$7.54M$13.69M$14.31M$20.03M$29.10M$64.14M$30.89M$28.75M$41.06M$27.01M
Free cash flow$13.94M$4.35M$30.48M$3.34M-$27.64M-$90.86M-$96.88M-$30.70M-$34.04M-$21.78M
Investing cash flow-$6.50M-$13.69M-$139.69M-$19.63M-$159.44M-$632.37M$517.00K$76.71M$12.86M-$12.34M
Financing cash flow-$25.87M-$4.09M$91.96M$159.47M$235.60M$725.28M$11.83M$4.55M$4.65M-$200.29M
Stock-based compensation$5.44M$6.44M$6.96M$10.00M$10.21M$22.46M$24.67M$24.63M$33.41M$41.32M
Depreciation & amortization$15.94M$15.60M$15.80M$20.35M$25.90M$30.19M$35.37M$37.45M$39.10M$36.07M

Quarterly figures are rebuilt from the year-to-date totals companies report — Q4 is the full year minus the first nine months, since no 10-Q is filed for it. Values are as filed; later restatements replace earlier ones. Fiscal years are labelled by the calendar year in which they end.